The data also argue that any competition between the FAP8-FL and folate-FL for binding to the anti-FL CAR must be minimal, since tumor eradication (Figure 3A), CAR T cell infiltration (Figure 3F), and IFNγ release (Figure 3H) all improved by concurrent administration of the two adapters. This evidence concerns the gene IFNG and neoplasm.